OncoSec Medical Incorporated (ONCS) Fundamental Analysis & Valuation

NASDAQ:ONCS • US68234L4059

Current stock price

0.2772 USD
+0.07 (+31.87%)
At close:
0.23 USD
-0.05 (-17.03%)
After Hours:

This ONCS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ONCS Profitability Analysis

1.1 Basic Checks

  • ONCS had negative earnings in the past year.
  • In the past year ONCS has reported a negative cash flow from operations.
ONCS Yearly Net Income VS EBIT VS OCF VS FCFONCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

  • The profitability ratios for ONCS are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ONCS Yearly ROA, ROE, ROICONCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300 -400 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ONCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCS Yearly Profit, Operating, Gross MarginsONCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ONCS Health Analysis

2.1 Basic Checks

  • ONCS has more shares outstanding than it did 1 year ago.
  • ONCS has a worse debt/assets ratio than last year.
ONCS Yearly Shares OutstandingONCS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
ONCS Yearly Total Debt VS Total AssetsONCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • ONCS has an Altman-Z score of -59.67. This is a bad value and indicates that ONCS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ONCS (-59.67) is worse than 92.77% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -59.67
ROIC/WACCN/A
WACCN/A
ONCS Yearly LT Debt VS Equity VS FCFONCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

  • A Current Ratio of 0.89 indicates that ONCS may have some problems paying its short term obligations.
  • ONCS has a Current ratio of 0.89. This is amonst the worse of the industry: ONCS underperforms 88.91% of its industry peers.
  • ONCS has a Quick Ratio of 0.89. This is a bad value and indicates that ONCS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ONCS has a worse Quick ratio (0.89) than 87.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.89
ONCS Yearly Current Assets VS Current LiabilitesONCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ONCS Growth Analysis

3.1 Past

  • ONCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.16%, which is quite impressive.
EPS 1Y (TTM)39.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.37%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCS Yearly EPS VS EstimatesONCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

0

4. ONCS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ONCS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCS Price Earnings VS Forward Price EarningsONCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCS Per share dataONCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ONCS Dividend Analysis

5.1 Amount

  • ONCS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ONCS Fundamentals: All Metrics, Ratios and Statistics

OncoSec Medical Incorporated

NASDAQ:ONCS (6/23/2023, 8:00:02 PM)

After market: 0.23 -0.05 (-17.03%)

0.2772

+0.07 (+31.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-15
Earnings (Next)N/A
Inst Owners0%
Inst Owner Change-97.83%
Ins Owners49.44%
Ins Owner Change0%
Market Cap1.65M
Revenue(TTM)N/A
Net Income(TTM)-29.39M
Analysts43.33
Price Target5.1 (1739.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.96%
Min EPS beat(2)9.96%
Max EPS beat(2)9.96%
EPS beat(4)3
Avg EPS beat(4)12.34%
Min EPS beat(4)9.96%
Max EPS beat(4)14.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-19.14
EYN/A
EPS(NY)-2.42
Fwd EYN/A
FCF(TTM)-4.19
FCFYN/A
OCF(TTM)-4.19
OCFYN/A
SpS0
BVpS-0.92
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.89
Altman-Z -59.67
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
EPS Next Y87.37%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.52%
OCF growth 3YN/A
OCF growth 5YN/A

OncoSec Medical Incorporated / ONCS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of OncoSec Medical Incorporated (ONCS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ONCS.


What is the valuation status for ONCS stock?

ChartMill assigns a valuation rating of 0 / 10 to OncoSec Medical Incorporated (ONCS). This can be considered as Overvalued.


What is the profitability of ONCS stock?

OncoSec Medical Incorporated (ONCS) has a profitability rating of 1 / 10.


How financially healthy is OncoSec Medical Incorporated?

The financial health rating of OncoSec Medical Incorporated (ONCS) is 0 / 10.


Can you provide the expected EPS growth for ONCS stock?

The Earnings per Share (EPS) of OncoSec Medical Incorporated (ONCS) is expected to grow by 87.37% in the next year.